Breast cancer is one of the most common cancers affecting women. Despite significant improvements in overall survival, it remains a significant cause of death worldwide. Genomic instability (GI) is a hallmark of cancer and plays a pivotal role in breast cancer development and progression. In the past decade, high-throughput technologies have provided a wealth of information that has facilitated the identification of a diverse repertoire of mutated genes and mutational processes operative across cancers. Here, we review recent findings on genomic alterations and mutational processes in breast cancer pathogenesis. Most importantly, we summarize the clinical challenges and opportunities to utilize omics-based signatures for better management of breast cancer patients and treatment decision-making.
|Authors||Kalimutho, Murugan; Nones, Katia; Srihari, Sriganesh; Duijf, Pascal H G; Waddell, Nicola; Khanna, Kum Kum|
|Journal||TRENDS IN PHARMACOLOGICAL SCIENCES|
|Funding Body||Cancer Council Queensland|